Discussion of Inventors’ Path in Expert’s Obviousness Opinion Warrants Partial Exclusion in Bench Trial

Jun 15, 2022

Reading Time : 2 min

The plaintiff in this case sought to exclude an expert’s obviousness opinion on several grounds, including failure to identify specific prior art combinations, mere conclusory statements on the motivation to combine, discussion of the inventors’ path and reliance on commercial motivations. While the district court rejected all but one of these grounds, noting that the threshold for precluding expert opinions is less critical in a bench trial setting, the district court agreed that the portion of the expert opinion that addressed the inventors’ path was inadmissible.

Specifically, the expert dedicated several pages in his report to discussing the plaintiff’s internal documents and deposition testimony of the inventors, which, according to the expert, demonstrated that the inventors followed a routine and obvious procedure to select a particular salt with expected properties. The expert then concluded that this path taken by the inventors in formulating the patented compound was obvious, which therefore provided further support for his own independent determination of obviousness.

Despite the expert’s clarification that his discussion of how the inventors arrived at the invention was not necessary for his obviousness determination, the district court nevertheless excluded this portion of the opinion. In doing so, the district court adhered to the Federal Circuit’s cautionary guidance against using the inventor’s path to render an invention obvious, as this would constitute hindsight, and therefore could never lead to a conclusion of obviousness. The district court further pointed to the defendant’s failure to show that the expert’s discussion of internal documents and inventor testimony described “routine testing”—which may be permissible under particular facts—and not an inventive “trial and error procedure” used to discover new compounds. By evaluating the obviousness of the invention through the eyes of the inventor, the district court found that the expert blurred the lines between the inventors’ work and the prior art, as well as between the level of ordinary skill in the art and the inventors’ potentially exceptional skill in the art. For this reason, the district court agreed to exclude those portions of the expert opinion from the bench trial.

Practice Tip: Even in the context of a bench trial, where the exclusion of expert testimony is less critical, experts should not exclusively rely on evidence of the inventive path taken by the inventors when making an obviousness determination. Because viewing the invention with the inventor’s own blueprint fails to properly evaluate the invention in the state of the art that existed at the time, courts are likely to view such evidence as impermissible hindsight. Accordingly, to the extent experts cite evidence of the steps the inventors took to arrive at the invention, they should also include additional, independent bases for obviousness, in the event the “inventors’ path” evidence is excluded.

Exelixis, Inc. v. MSN Laboratories Private Limited et al., 1:19-cv-02017 (D. Del. Apr. 20, 2022).

Share This Insight

Previous Entries

IP Newsflash

March 24, 2025

The Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) final written decision holding that the prior art exception of AIA Section 102(b)(2)(B) does not apply to a prior sale by an inventor when the sale is conducted in private. According to the Federal Circuit, a sale must disclose the relevant aspects of the invention to the public to qualify for the prior art exception of Section 102(b)(2)(B).

...

Read More

IP Newsflash

March 21, 2025

Under the Lanham Act, a plaintiff who prevails on a trademark infringement claim may be entitled to recover the “defendant’s profits” as damages. The Supreme Court in Dewberry Group, Inc. v. Dewberry Engineers Inc. unanimously construed “defendant’s profits” in 35 USC § 1117(a) to mean that only the named defendant’s profits can be awarded, not the profits of other related corporate entities. The Court, however, left open the possibility that other language in § 1117(a) may allow for damages linked to the profits of related entities, if properly raised and supported.

...

Read More

IP Newsflash

March 13, 2025

In a series of rulings on a motion in limine, the District of Delaware recently distinguished between what qualifies as being incorporated by reference and what does not for the purposes of an anticipation defense. In short, a parenthetical citation was held to be insufficient, while three passages discussing a cited reference met the test.

...

Read More

IP Newsflash

March 4, 2025

On February 28, 2025, the USPTO announced that it was rescinding former Director Vidal’s 2022 memorandum on discretionary denials by the Patent Trial and Appeal Board. The 2022 memorandum effectively narrowed the application of discretionary denials in cases with parallel district court litigation by specifying instances where discretionary denial could not be issued. With the withdrawal of the memorandum, individual PTAB panels will regain flexibility in weighing discretionary denials. While the long-term effect of that increased flexibility is not yet known, the immediate effect is likely to be a shift towards the discretionary analysis applied by PTAB panels before the issuance of the memorandum.

...

Read More

IP Newsflash

March 3, 2025

A District of Delaware judge recently granted a defendant’s motion to include a patent prosecution bar in its proposed protective order after determining that litigation counsel’s ability to practice before the Patent Office—without ever having represented the plaintiffs at the Patent Office in the past—weighed heavily in favor of the bar.

...

Read More

IP Newsflash

February 12, 2025

The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to satisfy the written description requirement. In so doing, the Federal Circuit explained that written description and enablement are evaluated based on the subject matter that is claimed, not the products that practice those claims. As a result, the patentee was not required to describe unclaimed, later-discovered features of the accused products despite the broad language in the claims that undisputedly covered the products.

...

Read More

IP Newsflash

January 24, 2025

The District of Delaware recently rejected a patentee’s argument that non-production of an opinion letter from counsel, combined with knowledge of the patent, warranted a finding that defendant induced infringement.

...

Read More

IP Newsflash

January 17, 2025

The District of Delaware recently denied a motion to dismiss a patent infringement complaint involving gene editing technology that sought relief under the Safe Harbor Provision of the Hatch-Waxman Act. Specifically, the court found the patentee’s complaint sufficiently alleged at least some uses of the claimed technology that, when taken as true, were not solely uses of a “patented invention” that were “reasonably related” to an FDA submission.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.